Risk factors for chemotherapy-associated liver injuries: A multivariate analysis of a group of 146 patients with colorectal metastases

Surgery

Volumn 145, Issue 4, 2009, Pages 362-371

  Brouquet, Antoine ^a,b   Benoist, Stéphane ^a,b   Julie, Catherine ^a,b   Penna, Christophe ^a,b   Beauchet, Alain ^a,b   Rougier, Philippe ^a,b   Nordlinger, Bernard ^a,b  

^a HÔPITAL AMBROISE PARÉ   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FLUOROURACIL; FOLINIC ACID; GAMMA GLUTAMYLTRANSFERASE; IRINOTECAN; OXALIPLATIN;

ADULT; ARTICLE; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEART DISEASE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RISK FACTOR;

AGED; ANTINEOPLASTIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; FATTY LIVER; FEMALE; HEPATITIS, TOXIC; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ORGANOPLATINUM COMPOUNDS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 62349101530     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2008.12.002     Document Type: Article

References (33)

1. Nordlinger B., and Benoist S. Benefits and risks of neoadjuvant therapy for liver metastases. J Clin Oncol 24 (2006) 4954-4955
2. Khatri V.P., Petrelli N.J., and Belghiti J. Extending the frontiers of surgical therapy for hepatic colorectal metastases: is there a limit?. J Clin Oncol 23 (2005) 8490-8499
3. Adam R., Delvart V., Pascal G., Valeanu A., Castaing D., Azoulay D., et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240 (2004) 644-657
4. Leonard G.D., Brenner B., and Kemeny N.E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 23 (2005) 2038-2048
5. Allen P.J., Kemeny N., Jarnagin W., DeMatteo R., Blumgart L., and Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 7 (2003) 109-115
6. Nordlinger B., Sorbye H., Glimelius B., Poston G.J., Schlag P.M., Rougier P., et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371 (2008) 1007-1016
7. Karoui M., Penna C., Amin-Hashem M., Mitry E., Benoist S., Franc B., et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243 (2006) 1-7
8. Aloia T., Sebagh M., Plasse M., Karam V., Lévi F., Giacchetti S., et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24 (2006) 4983-4990
9. Vauthey J.N., Pawlik T.M., Ribero D., Wu T.T., Zorzi D., Hoff P.M., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
10. Nakano H., Oussoultzoglou E., Rosso E., Casnedi S., Chenard-Neu M.P., Dufour P., et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247 (2008) 118-124
11. Parikh A.A., Gentner B., Wu T.T., Curley S.A., Ellis L.M., and Vauthey J.N. Perioperative complications in patients undergoing major liver resection with or without neoadjuvant chemotherapy. J Gastrointest Surg 7 (2003) 1082-1088
12. Bilchik A.J., Poston G., Curley S.A., Strasberg S., Saltz L., Adam R., et al. Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 23 (2005) 9073-9078
13. Rubbia-Brandt L., Audard V., Sartoretti P., Roth A.D., Brezault C., Le Charpentier M., et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15 (2004) 460-466
14. Kooby D.A., Fong Y., Suriawinata A., Gonen M., Allen P.J., Klimstra D.S., et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7 (2003) 1034-1044
15. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
16. Peppercorn P.D., Reznek R.H., Wilson P., Slevin M.L., and Gupta R.K. Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer. Br J Cancer 77 (1998) 2008-2011
17. Moertel C.G., Fleming T.R., Macdonald J.S., Haller D.G., and Laurie J.A. Hepatic toxicity associated with fluorouracil plus levamisole adjuvant therapy. J Clin Oncol 11 (1993) 2386-2390
18. de Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
19. Douillard J.Y., Cunningham D., Roth A.D., Navarro M., James R.D., Karasek P., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
20. Kleiner D.E., Brunt E.M., Van Natta M., Behling C., Contos M.J., Cummings O.W., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
21. Pawlik T.M., Olino K., Gleisner A.L., Torbenson M., Schulick R., and Choti M.A. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 11 (2007) 860-868
22. Welsh F.K., Tilney H.S., Tekkis P.P., John T.G., and Rees M. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer 96 (2007) 1037-1042
23. Reddy S.K., Morse M.A., Hurwitz H.I., Bendell J.C., Gan T.J., Hill S.E., et al. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206 (2008) 96-106
24. Tisman G., MacDonald D., Shindell N., Reece E., Patel P., Honda N., et al. Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22 (2004) 3202-3204
25. Torres D.M., and Harrison S.A. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology 134 (2008) 1682-1698
26. Cho C.S., Curran S., Schwartz L.H., Kooby D.A., Klimstra D.S., Shia J., et al. Preoperative radiographic assessment of hepatic steatosis with histologic correlation. J Am Coll Surg 206 (2008) 480-488
27. Attal M., Huguet F., Rubie H., Huynh A., Charlet J.P., Payen J.L., et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: a prospective, randomized trial. Blood 79 (1992) 2834-2840
28. Or R., Nagler A., Shpilberg O., Elad S., Naparstek E., Kapelushnik J., et al. Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 61 (1996) 1067-1071
29. Gluckman E., Jolivet I., Scrobohaci M.L., Devergie A., Traineau R., Bourdeau-Esperou H., et al. Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol 78 (1991) 138-139
30. Terres W., Beythien C., Kupper W., and Bleifeld W. Effects of aspirin and prostaglandin E1 on in vitro thrombolysis with urokinase. Evidence for a possible role of inhibiting platelet activity in thrombolysis. Circulation 79 (1989) 1309-1314
31. Benoist S., Salabert A.S., Penna C., Karoui M., Julié C., Rougier P., et al. Portal triad clamping (TC) or hepatic vascular exclusion (VE) for major liver resection after prolonged neoadjuvant chemotherapy? A case-matched study in 60 patients. Surgery 140 (2006) 396-403
32. Zorzi D., Laurent A., Pawlik T.M., Lauwers G.Y., Vauthey J.N., and Abdalla E.K. Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94 (2007) 274-286
33. Brancatelli G., Vilgrain V., Federle M.P., Hakime A., Lagalla R., Iannaccone R., et al. Budd-Chiari syndrome: spectrum of imaging findings. Am J Roentgenol 188 (2007) 168-176